CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Concord Medical Services Holdings (NYSE: CCM)
›
Concord Medical Services Holdings (NYSE: CCM) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 610 employees.
The shares were at 3.660 USD on 19 November 2026, down 10.3% over 52 weeks. Its 52-week range is 2.785 USD to 6.800 USD: the price is 46.2% below the high and 31.4% above the low.
Its market capitalisation is 15.59M USD.
Concord Medical Services Holdings reports return on equity of 4.4%, an operating margin of -52.0% and revenue up 57.4% year over year.
Its debt exceeds its cash by 3.34B CNY. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.